NCT07924618 Ocular Changes in Patients Using Tirzepatide or Semaglutide
| NCT ID | NCT07924618 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istanbul University |
| Condition | Type 2 Diabetes Mellitus |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2027-09-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2026-03-01 with a primary completion date of 2027-09-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective observational study aims to evaluate ocular structural and microvascular changes in adults with obesity who are receiving semaglutide or tirzepatide as part of routine clinical care. Participants with and without type 2 diabetes mellitus will be included. Participants will undergo ophthalmologic examinations at baseline and during follow-up. Changes in optic nerve head parameters, retinal thickness, retinal and choroidal microvascular parameters, and choroidal thickness will be assessed using optical coherence tomography (OCT), optical coherence tomography angiography (OCT-A), and other routine ophthalmologic examination methods. The study will compare ocular measurements obtained at baseline and during follow-up to investigate changes associated with semaglutide or tirzepatide treatment over a period of up to 18 months.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Diagnosis of obesity * Receiving semaglutide or tirzepatide as part of routine clinical care * Participants with or without type 2 diabetes mellitus * Availability for baseline and follow-up ophthalmologic examinations Exclusion Criteria: * Age under 18 years * Not receiving semaglutide or tirzepatide * Inability to complete the required ophthalmologic examinations or imaging assessments
Frequently Asked Questions
Who can join the NCT07924618 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Type 2 Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07924618 currently recruiting?
Yes, NCT07924618 is actively recruiting participants. Visit ClinicalTrials.gov or contact Istanbul University to inquire about joining.
Where is the NCT07924618 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07924618 clinical trial?
NCT07924618 is sponsored by Istanbul University. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.